SCHEMBL20504499

SCHEMBL20504499

CCOC(=O)c1cnc2c(N(Cc3ccc(OC)cc3)C3CC3)cc(Cl)nn12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ P2RY12 Q9H244 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ IDO1 P14902 1/20 0.38
▸ FAAH O00519 2/20 0.37
▸ PDE1B Q01064 5/20 0.36
▸ MAOB P27338 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA2B P29275 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ UCHL1 P09936 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20504495 0.89 PDE1B (0.38) PDE1BHTR2AMEN1KMT2A
SCHEMBL16794693 0.87 MAPT (0.42) MAPTP2RY12GAAIDO1PDE1B
SCHEMBL31245703 0.84 MAPT (0.40) MAPTP2RY12GAAIDO1PDE1B
SCHEMBL16794646 0.83 MAPT (0.40) MAPTP2RY12GAAIDO1PDE1B
SCHEMBL3723311 0.82 MALT1 (0.37) MAPTPDE1BLMNASMN1; SMN2MEN1
SCHEMBL13421283 0.82 PDE1B (0.39) PDE1B
SCHEMBL3725541 0.81 FAAH (0.37) FAAHPDE1BSMN1; SMN2
SCHEMBL3720947 0.80 NR3C1 (0.35) MAPTLMNASMN1; SMN2MEN1KMT2A
SCHEMBL3719962 0.80 NOD2 (0.37) LMNA
SCHEMBL2358590 0.79 PDE1B (0.37) PDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3377496-B1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2020-09-16 — — EP disclosed
EP-3377496-B1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2020-09-16 — — EP disclosed
US-10479793-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses BRISTOL-MYERS SQUIBB COMPANY (US) 2019-11-19 — — US disclosed
US-10479793-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses BRISTOL-MYERS SQUIBB COMPANY (US) 2019-11-19 — — US disclosed
US-20180325899-A1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES BRISTOL MYERS SQUIBB CO (US) 2018-11-15 — — US disclosed
EP-3377496-A1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES Bristol-Myers Squibb Company (US) 2018-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10479793-B2 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses TYK2, IL2, JAK3 MAPT 3495/4885P2RY12 334/4885GAA 3535/4885
US-20180325899-A1 IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES TYK2, IL2, JAK3 MAPT 3495/4885P2RY12 334/4885GAA 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback